Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.58 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | CDK1 | P06493 | 3/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
| ▸ | CDK7 | P50613 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.49 |
| ▸ | CCNH | P51946 | 1/20 | 0.49 |
| ▸ | POLA1 | P09884 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.37 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.37 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5072707 | 0.81 | CDK2 (0.58) | CDK2PAK1ALDH1A1KDM4ECDK1 | |
| SCHEMBL9356697 | 0.81 | CDK2 (0.58) | CDK2PAK1ALDH1A1KDM4ECDK1 | |
| SCHEMBL5828213 | 0.81 | CDK2 (0.58) | CDK2PAK1ALDH1A1KDM4ECDK1 | |
| SCHEMBL30151962 | 0.79 | CDK2 (0.56) | CDK2PAK1ALDH1A1KDM4ECDK1 | |
| SCHEMBL4511045 | 0.79 | CDK2 (0.53) | CDK2PAK1ALDH1A1KDM4ECDK1 | |
| Isopropyl Alcohol SCHEMBL10551705 | 0.78 | CDK2 (0.51) | CDK2PAK1ALDH1A1KDM4ECDK1 | |
| SCHEMBL5196386 | 0.78 | CDK2 (0.51) | CDK2PAK1ALDH1A1KDM4ECDK1 | |
| SCHEMBL4511042 | 0.78 | CDK2 (0.51) | CDK2PAK1ALDH1A1KDM4ECDK1 | |
| SCHEMBL6675329 | 0.78 | PAK1 (0.52) | CDK2PAK1ALDH1A1KDM4ECDK1 | |
| SCHEMBL5436674 | 0.77 | CDK2 (0.54) | CDK2PAK1ALDH1A1KDM4ECDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968444-B2 | Methods for generating bispecific functional agents | ABZYME THERAPEUTICS LLC (US) | 2021-04-06 | — | — | US | claimed |
| US-20180334666-A1 | METHODS FOR GENERATING BISPECIFIC FUNCTIONAL AGENTS | ABZYME THERAPEUTICS LLC | 2018-11-22 | — | — | US | claimed |
| US-7790374-B2 | Process for sequence saturation mutagenesis (SeSaM) | BASF AKTIENGESELLSCHAFT (DE) | 2010-09-07 | — | — | US | claimed |
| EP-2192905-A2 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | Lubin, Adam (US) | 2010-06-09 | — | — | EP | claimed |
| WO-2009032057-A2 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | LUBIN ADAM (US) | 2009-03-12 | — | — | WO | claimed |
| EP-1670914-B1 | A PROCESS FOR SEQUENCE SATURATION MUTAGENESIS (SESAM) | BASF AG (DE) | 2008-01-23 | — | — | EP | claimed |
| US-20060223148-A1 | Process for sequence saturation mutagenesis (sesam) | BASF AKTIENGESCHAFT (DE) | 2006-10-05 | — | — | US | claimed |
| EP-1670914-A1 | A PROCESS FOR SEQUENCE SATURATION MUTAGENESIS (SESAM) | BASF AKTIENGESELLSCHAFT (DE) | 2006-06-21 | — | — | EP | claimed |
| EP-1572097-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2005-09-14 | — | — | EP | claimed |
| WO-2005035757-A1 | A PROCESS FOR SEQUENCE SATURATION MUTAGENESIS (SESAM) | BASF AKTIENGESELLSCHAFT (DE) | 2005-04-21 | — | — | WO | claimed |
| WO-2004028481-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2004-04-08 | — | — | WO | claimed |
| US-11618880-B2 | Compositions comprising bacterial strains and use thereof in controlling pathogenic microorganisms | BETTER AIR INTERNATIONAL LIMITED (HK) | 2023-04-04 | — | — | US | disclosed |
| US-10968444-B2 | Methods for generating bispecific functional agents | ABZYME THERAPEUTICS LLC (US) | 2021-04-06 | — | — | US | disclosed |
| EP-3600329-A1 | COMPOSITIONS AND METHOD OF TREATING CANCER | The Regents of The University of California (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20180334666-A1 | METHODS FOR GENERATING BISPECIFIC FUNCTIONAL AGENTS | ABZYME THERAPEUTICS LLC | 2018-11-22 | — | — | US | disclosed |
| WO-2001025255-A9 | NOVEL ZINC FINGER PROTEIN | BAYLOR COLLEGE MEDICINE (US) | 2002-09-26 | — | — | WO | disclosed |
| WO-2001025255-A2 | NOVEL ZINC FINGER PROTEIN | BAYLOR COLLEGE OF MEDICINE (US) | 2001-04-12 | — | — | WO | disclosed |
| WO-1998001459-A1 | NOVEL N-ALKOXYADENINE DERIVATIVES ACTING AS CYTOKINE INHIBITORS | NOVO NORDISK A/S (DK) | 1998-01-15 | — | — | WO | disclosed |
| WO-1997033590-A1 | A METHOD OF TREATING DISORDERS RELATED TO CYTOKINES IN MAMMALS | NOVO NORDISK A/S (DK) | 1997-09-18 | — | — | WO | disclosed |
| WO-1997033591-A1 | A METHOD OF TREATING DISORDERS RELATED TO CYTOKINES IN MAMMALS | NOVO NORDISK A/S (DK) | 1997-09-18 | — | — | WO | disclosed |